Novel pharmacotherapies and breakthroughs in psoriatic arthritis treatment

Advances in mechanism-based and metabolic-targeted therapies enable more individualized PsA management, improving the likelihood of achieving treatment targets. Ongoing challenges include early recognition, treatment of refractory disease, and long-term safety assessment. Progress in patient-centered therapy selection and precision medicine is expected to enhance outcomes, reduce disease burden, and optimize healthcare resources. Emerging pharmacotherapies continue to expand the treatment landscape, supporting a shift toward more effective, durable, and personalized management strategies.